Novo Nordisk A/S

(PINK:NONOF)

Latest On Novo Nordisk A/S (NONOF):

Date/Time Type Description Signal Details
2024-03-22 05:57 ESTDividendA dividend of $6.4 has been announced on Jan 31, 2024. It will be paid Mar 26, 2024 with an ex-dividend date of Mar 22, 2024.Neutral
2023-08-18 05:56 ESTDividendA dividend of $6 has been announced on Aug 10, 2023. It will be paid Aug 22, 2023 with an ex-dividend date of Aug 18, 2023.Neutral
2023-05-12 16:36 ESTNewsObesity review: World Health Organization weighs in on weight loss drugsN/A
2023-05-04 18:40 ESTNewsNovo Nordisk A/S (NVO) Q1 2023 Earnings Call TranscriptN/A
2023-05-04 05:49 ESTNewsNovo Nordisk GAAP EPS of DKK8.78, revenue of DKK53.37B; updates FY23 outlookN/A
2023-05-04 05:49 ESTNewsNovo Nordisk stock dips as Wegovy sales miss, drug's US supply hit amid demandN/A
2023-04-13 12:37 ESTNewsNovo Nordisk: Maybe It's Time To Trim The Position A Little BitN/A
2023-04-12 09:50 ESTNewsNovo Nordisk to pay $75M initially to Aspect Biosystems to develop new drugs for diabetes/obesityN/A
2023-04-03 12:35 ESTNewsNovo Nordisk A/S (NVO) Q4 2022 Earnings Call TranscriptN/A
2023-03-24 18:39 ESTNewsNovo Nordisk: Regarding FY22 And The Serendipity Of GLP-1sN/A
2023-03-24 05:55 ESTDividendA dividend of $8.15 has been announced on Mar 22, 2023. It will be paid Mar 28, 2023 with an ex-dividend date of Mar 24, 2023.Neutral
2023-03-02 08:59 ESTNewsNovo Nordisk to boost R&D footprint in Boston; 100 jobs cuts in Seattle, IndianapolisN/A
2023-02-15 17:44 ESTNewsNovo Nordisk: Attractive Market But Likely No Margin Of SafetyN/A
2023-02-10 06:46 ESTNewsNovo Nordisk, Heartseed start dosing in trial of novel cell therapy for heart failureN/A
2023-02-02 11:19 ESTNewsNovo Nordisk A/S 2022 Q4 - Results - Earnings Call PresentationN/A
2023-02-01 10:00 ESTNewsNovo Nordisk GAAP EPS of DKK 6.02, revenue of DKK 48.09B; initiates FY23 guidanceN/A
2023-02-01 10:00 ESTNewsNovo Nordisk Q4 revenue grows on diabetes/obesity drugs, insulin sales dip; provides FY23 outlookN/A
2023-01-12 15:58 ESTNewsEli Lilly, Novo, Sanofi and leading PBMs accused in California over insulin pricesN/A
2022-12-12 04:54 ESTNewsLilly, Novo dominance in weight loss market intact despite Amgen entry – BofAN/A
2022-12-01 20:25 ESTNewsBabylon subsidiary, Novo Nordisk team to expand diabetes awareness and care in RwandaN/A
2022-11-04 10:52 ESTNewsNovo Nordisk: Impressive Performance, But Still PriceyN/A
2022-11-03 18:06 ESTNewsNovo Nordisk A/S 2022 Q3 - Results - Earnings Call PresentationN/A
2022-11-03 18:06 ESTNewsNovo Nordisk A/S (NVO) Q3 2022 Investor Call TranscriptN/A
2022-11-02 08:55 ESTNewsNovo Nordisk reports Q3 results; updates FY22 guidance rangeN/A
2022-11-02 08:55 ESTNewsNovo Nordisk surges on raised FY22 outlook as Ozempic drives Q3 salesN/A
2022-08-23 19:42 ESTNewsNovo Nordisk: Assessing Hype Towards Obesity Care Following The Q2 Results Drop, Story Is IntactN/A
2022-08-04 03:57 ESTNewsNovo Nordisk A/S 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-04 03:57 ESTNewsNovo Nordisk A/S (NVO) CEO Lars Fruergaard Joergensen on Q2 2022 Results - Earnings Call TranscriptN/A
2022-06-06 11:47 ESTNewsNovo Nordisk A/S (NVO) Presents at ADA 82nd Scientific Sessions (Transcript)N/A
2022-04-20 20:54 ESTNewsNovo Nordisk: Firing On All Cylinders, Which Is Reflected By The Share PriceN/A
2022-03-25 05:56 ESTDividendA dividend of $6.9 has been announced on Feb 2, 2022. It will be paid Mar 29, 2022 with an ex-dividend date of Mar 25, 2022.Neutral
2022-02-03 03:43 ESTNewsNovo Nordisk A/S (NVO) CEO Lars Jorgensen on Q4 2021 Results - Earnings Call TranscriptN/A
2022-02-02 10:56 ESTNewsNovo Nordisk A/S 2021 Q4 - Results - Earnings Call PresentationN/A
2021-11-19 02:10 ESTNewsNovo Nordisk Enhances Metabolic Disorder Pipeline With RNAi Drug Maker DicernaN/A
2021-11-05 16:20 ESTNewsNovo Nordisk A/S 2021 Q3 - Results - Earnings Call PresentationN/A
2021-11-03 22:18 ESTNewsNovo Nordisk A/S (NVO) CEO Lars Fruergaard Jorgensen on Q3 2021 Results - Earnings Call TranscriptN/A
2021-08-16 05:58 ESTDividendA dividend of $3.5 has been announced on Nov 30, -0001. It will be paid Aug 18, 2021 with an ex-dividend date of Aug 16, 2021.Neutral
2021-08-07 09:42 ESTNewsNovo Nordisk: Exceptional Performance But OvervaluedN/A
2021-08-05 16:36 ESTNewsNovo Nordisk A/S 2021 Q2 - Results - Earnings Call PresentationN/A
2021-08-05 16:36 ESTNewsNovo Nordisk A/S (NVO) CEO Lars Jorgensen on Q2 2021 Results - Earnings Call TranscriptN/A
2021-07-22 10:07 ESTNewsNovo Nordisk: Pricey, But A Great Long-Term InvestmentN/A
2021-05-06 02:18 ESTNewsNovo Nordisk A/S 2021 Q1 - Results - Earnings Call PresentationN/A
2021-05-06 02:16 ESTNewsNovo Nordisk A/S (NVO) CEO Lars Jorgensen on Q1 2021 Results - Earnings Call TranscriptN/A
2021-03-26 05:57 ESTDividendA dividend of $5.85 has been announced on Nov 30, -0001. It will be paid Mar 30, 2021 with an ex-dividend date of Mar 26, 2021.Neutral
2021-02-22 12:01 ESTNewsObesity Offers Tremendous Potential For Novo NordiskN/A
2021-02-05 21:04 ESTFinancialsCompany financials have been released.Neutral
2021-02-04 04:27 ESTNewsNovo Nordisk A/S 2020 Q4 - Results - Earnings Call PresentationN/A
2021-02-04 04:26 ESTNewsNovo Nordisk A/S (NVO) CEO Lars Jørgensen on Q4 2020 Results - Earnings Call TranscriptN/A
2021-01-19 19:59 ESTNewsNovo Nordisk: An Outstanding Company For The Long TermN/A
2021-01-12 15:57 ESTNewsNovo Nordisk A/S (NVO) CEO Lars Jørgensen Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)N/A

About Novo Nordisk A/S (NONOF):

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

NONOF Quotes by TradingView

See Advanced Chart

General

  • Name Novo Nordisk A/S
  • Symbol NONOF
  • Type Common Stock
  • Exchange PINK
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 44,723
  • Last Split Factor5:1
  • Last Split Date2014-01-02
  • Fiscal Year EndDecember
  • Web URLhttp://www.novonordisk.com
View More

Valuation

  • Trailing PE 28.53
  • Forward PE 23.92
  • Price/Sales (Trailing 12 Mt.) 8.35
  • Price/Book (Most Recent Quarter) 16.51
  • Enterprise Value Revenue 1.29
  • Enterprise Value EBITDA 2.77
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Profit Margin 33%
  • Return on Assets 25%
  • Return on Equity 70%
  • Earnings Per Share $2.46
  • Revenue Per Share $0
  • Gross Profit 106.01 billion
  • Quarterly Earnings Growth -0.9%
View More

ESG Rating

  • Rating Date 2019-01-01
  • ESG Score 21.83
  • Environment Score 0.84
  • Social Score 10.95
  • Governance Score 9.21
  • Controversy Level 3
View More

Highlights

  • Market Capitalization 159.3 billion
  • PEG Ratio 3.55
  • Book Value Per Share $3.08
View More

Share Statistics

  • Shares Outstanding 1.77 billion
  • Shares Float 1.65 billion
  • % Held by Insiders <1%
  • % Held by Institutions 31.84%
View More

Technicals

  • Beta 0.29
  • 52 Week High $77.4
  • 52 Week Low $47.3
  • 50 Day Moving Average 72.08
  • 200 Day Moving Average 70.02
View More

Dividends

  • Forward Annual Dividend Rate $1.91
  • Forward Annual Dividend Yield 2.63%
  • Payout Ratio 84%
  • Dividend Date 2018-03-27
  • ExDividend Date 2021-03-26
  • Dividend Per Share $1.23
  • Dividend Yield 0%
View More

Novo Nordisk A/S (NONOF) Dividend Calendar:

NONOF's last dividend payment was made to shareholders on March 27, 2018.
Novo Nordisk A/S pays out 84% of its earnings out as a dividend.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Novo Nordisk A/S (NONOF) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312020-12-31$32.14 billion$0.64
2020-09-302020-12-31$N/A$0.66
2020-06-302020-09-30$N/A$0.70$4.33-83.93%
2020-03-312020-06-30$33.88 billion$0.68$4.68-85.41%
2019-12-312020-03-31$32.42 billion$0.75$3.81-80.41%
2019-09-302019-12-31$30.28 billion$0.55$4.12-86.53%
2019-06-302019-09-30$30.04 billion$0.63$4.04-84.5%
2019-03-312019-06-30$29.29 billion$0.61$4.09-84.99%
2018-12-312019-03-31$29.73 billion$0.66$3.71-82.34%
2018-09-302018-12-31$27.76 billion$0.54$3.91-86.17%
2018-06-302018-09-30$27.41 billion$0.58$4.16-86%
2018-03-312018-06-30$26.93 billion$0.67$4.10-83.71%
2017-12-312018-03-31$27.99 billion$0.73$3.51-79.28%
2017-09-302017-12-31$26.61 billion$0.54$3.80-85.76%
2017-06-302017-09-30$37.3 billion$0.63$3.87-83.75%
2017-03-312017-06-30$28.45 billion$0.62$3.64-83.08%
2016-12-312017-03-31$0.58$3.53-83.5%
2016-09-302016-12-31$0.49$3.76-86.98%
2016-06-302016-09-30$0.58$3.90-85.03%
2016-03-312016-06-30$0.59$3.62-83.84%
2015-12-312016-03-31$0.57$3.34-83.02%
2015-09-302015-12-31$0.47$3.29-85.73%
2015-06-302015-09-30$0.49$3.19-84.71%
2015-03-312015-06-30$0.48$3.31-85.43%
2014-12-312015-03-31$0.55$2.47-77.94%
2014-09-302014-12-31$0.41$2.60-84.31%
2014-06-302014-09-30$0.42
2014-03-312014-06-30$0.49
2013-12-312014-03-31$0.45
2013-09-302013-12-31$0.42
2013-06-302013-09-30$0.43
2013-03-312013-06-30$0.43
2012-12-312013-03-31$0.38
2012-09-302012-12-31$0.37
2012-06-302012-09-30$0.36
2012-03-312012-06-30$0.33
2011-12-312012-03-31$0.30
2011-09-302011-12-31$0.29
2011-06-302011-09-30$0.27
2011-03-312011-06-30$0.28
2010-12-312011-03-31$0.27
2010-09-302010-12-31$0.25
2010-06-302010-06-30$0.21
2010-03-312010-03-31$0.21
2009-12-312009-12-31$0.15
2009-09-302009-09-30$0.18
2009-06-302009-06-30$0.18
2009-03-312009-03-31$0.15
2008-12-312008-12-31$0.13
2008-09-302008-09-30$0.17
2008-06-302008-06-30$0.17
2008-03-312008-03-31$0.14
2005-12-312005-12-31$0.06

Novo Nordisk A/S (NONOF) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Novo Nordisk A/S (NONOF) Chart:

Novo Nordisk A/S (NONOF) News:

Below you will find a list of latest news for Novo Nordisk A/S (NONOF) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Novo Nordisk A/S (NONOF) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Novo Nordisk A/S (NONOF) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link